Human Angiopoietin-1 / Ang-1
Slide this table
| Cat-Nr. | 300-048 |
| Size | 20 µg |
| Price | 199 € |
| Source | HeLa cells |
| Label | His-Tag |
| Formulation | lyophilized |
| Purity Confirmation | > 95% by SDS-PAGE & HPLC analyses |
| Length [aa] | 485 |
| Molecular Weight | 60.0-70.0 kDa |
| Endotoxin Levels | < 0.1 ng/µg of protein (<1EU/µg) |
| Biological Activity | Determined by its ability to induce adhesion of human umbilical vein endothelial cells (HUVEC). |
| Species Reactivity | Human |
| Buffer | 20 mM Sodium Phosphate, pH 7.5 + 200 mM NaCl + 5% Trehalose |
| Reconstitution | Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C. |
| Stability and Storage | The lyophilized protein is stable at room temperature for 1 month and at 4°C for 3 months. Reconstituted working aliquots are stable for 1 week at 2°C to 8°C and for 3 months at -20°C to -80°C. |
| Synonyms | ANGPT1; AGP1; AGPT; ANG1; KIAA0003 |
| Description | Angiopoietin-1 (ANG-1) is a secreted ligand for Tie-2, a tyrosine-kinase receptor expressed primarily on vascular endothelial cells and early hematopoietic cells. ANG-1/Tie-2 signaling promotes angiogenesis during the development, remodeling, and repair of the vascular system. Transgenic mice lacking expression of either ANG-1 or Tie-2 fail to develop a fully functional cardiovascular system and die before birth. Postnatally, the angiogenic activity of ANG-1/Tie-2 is required during normal tissue repair and remodeling of the female endometrium in the menstrual cycle. ANG-1/Tie-2 signaling appears to be regulated by Angiopoietin-2 (ANG-2), a natural antagonist for Tie-2 that exerts its effects through an internal autocrine loop mechanism. In addition to suppressing endothelial cell activation by inhibiting the expression of adhesion and inflammatory molecules, ANG-1 enhances endothelial cell survival and capillary morphogenesis, and lessens capillary permeability. As such, ANG-1 has potential to become an effective therapeutic agent for treating various endothelium disorders, including several severe human pulmonary diseases. The efficacy of cell-based Ang-1 gene therapy for acute lung injury (ALI) has recently been studied in a rat model of ALI. The results of this study show that such therapy can markedly improve lung condition and suggest that ANG-1 therapy may represent a potential new strategy for the treatment and/or prevention of acute respiratory distress injury (ARDI), a significant cause of morbidity and mortality in critically ill patients. Recombinant Human ANG-1, derived from HeLa cells, is a C-terminal histidine tagged glycoprotein which migrates with an apparent molecular mass of 60.0 – 70.0 kDa by SDS-PAGE under reducing conditions. Sequencing analysis shows N-terminal sequences starting with Ser-20 and with Asp-70 of the 498 amino acid precursor protein. The calculated molecular weight of Recombinant Human ANG-1 is 56.3 kDa. |
| Protein Sequence | SNQRRSPENS GRRYNRIQHG QCAYTFILPE HDGNCRESTT DQYNTNALQR DAPHVEPDFS SQKLQHLEHV MENYTQWLQK LENYIVENMK SEMAQIQQNA VQNHTATMLE IGTSLLSQTA EQTRKLTDVE TQVLNQTSRL EIQLLENSLS TYKLEKQLLQ QTNEILKIHE KNSLLEHKIL EMEGKHKEEL DTLKEEKENL QGLVTRQTYI IQELEKQLNR ATTNNSVLQK QQLELMDTVH NLVNLCTKEG VLLKGGKREE EKPFRDCADV YQAGFNKSGI YTIYINNMPE PKKVFCNMDV NGGGWTVIQH REDGSLDFQR GWKEYKMGFG NPSGEYWLGN EFIFAITSQR QYMLRIELMD WEGNRAYSQY DRFHIGNEKQ NYRLYLKGHT GTAGKQSSLI LHGADFSTKD ADNDNCMCKC ALMLTGGWWF DACGPSNLNG MFYTAGQNHG KLNGIKWHYF KGPSYSLRST TMMIRPLDFH HHHHH |
| Uniprot ID | Q15389 |
| Protein RefSeq | NP_001137.2 |
| mRNA RefSeq | NM_001146 |
Reference
- Angiopoietin-2 Stimulation of Endothelial Cells Induces αvβ3 Integrin Internalization and Degradation. M. Thomas et al., J Biol Chem. 2010 Jul 30; 285(31): 23842–23849.
All prices plus VAT + possible delivery charges